Hemab Therapeutics Holdings
COAG
28.70
+0.33
+1.16%
Hemab Therapeutics Holdings
US · COAG
#3007 by market cap
Listed 2026
28.70
+0.33
+1.16%
Live - 5344 symbols - heartbeat 53s ago
· 2026-10-08 02:52
After-hours
28.70
0.00%
Overnight
28.37
-1.15%
- Market cap
- 1.34B
- P/E (TTM)i
- -16.11
- P/Bi
- 2.95
- EPSi
- -1.45
- Div yieldi
- 0.00%
- 52W posi
- 18%
Reader sentiment
Are you bullish or bearish on COAG?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 8.97M | 10.49M |
| Research & development | 41.41M | 59.63M |
| Operating profit | -50.38M | -70.12M |
| Pretax profit | -48.52M | -64.14M |
| Tax | 185.00K | -227.00K |
| Net profit | -48.71M | -63.91M |
| Basic EPS | -2 | -2 |
| Diluted EPS | -1.77 | -2.33 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 2.46M | 3.18M | 4.15M | 5.74M |
| Research & development | 14.10M | 12.87M | 19.46M | 20.34M |
| Operating profit | -16.56M | -16.06M | -23.61M | -26.08M |
| Pretax profit | -15.50M | -12.21M | -22.68M | -24.05M |
| Tax | -190.00K | 4.00K | 12.00K | 97.00K |
| Net profit | -15.31M | -12.21M | -22.69M | -24.15M |
| Basic EPS | -1 | 0 | -1 | -1 |
| Diluted EPS | -0.56 | -0.44 | -0.51 | -0.80 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 93.24M | 192.55M |
| Cash & ST investments | 88.33M | 185.49M |
| Inventory | -- | -- |
| Total assets | 96.28M | 194.78M |
| Total current liabilities | 6.69M | 10.68M |
| Short-term debt | 669.00K | 647.00K |
| Long-term debt | -- | -- |
| Total liabilities | 211,551,000.00 | 371,418,000.00 |
| Total equity | -115.27M | -176.64M |
| Retained earnings | -117.95M | -181.86M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 169.43M | 464.00M |
| Cash & ST investments | -- | -- | 163.53M | 457.46M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 175.26M | 467.78M |
| Total current liabilities | -- | -- | 13.19M | 12.94M |
| Short-term debt | -- | -- | 544.00K | 460.00K |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 373,876,000.00 | 13,510,000.00 |
| Total equity | -- | -- | -198.62M | 454.27M |
| Retained earnings | -- | -- | -204.55M | -228.70M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -45.59M | -61.48M |
| Depreciation & amortization | 248.00K | 304.00K |
| Free cash flow | -45.87M | -61.49M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 74.41M | 87.97M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -13.03M | -15.33M | -21.58M | -22.64M |
| Depreciation & amortization | 75.00K | 77.00K | 73.00K | 75.00K |
| Free cash flow | -13.05M | -15.33M | -21.70M | -22.66M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 55.35M | 61.49M | 49.86M | 237.37M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -50.59 | -43.92 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 13.95 | 18.03 |
| Quick ratioi | 13.45 | 17.62 |
| Debt / assetsi | 1.79 | 0.63 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -18.32 |
| ROA %i | -- | -- | -40.68 | -17.79 |
| ROIC %i | -- | -- | -- | -18.97 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 12.85 | 35.85 |
| Quick ratioi | -- | -- | 12.51 | 35.48 |
| Debt / assetsi | -- | -- | 0.61 | 0.22 |
| LT debt / equityi | -- | -- | -- | 0.12 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-08 02:52:22 · For reference only, not investment advice and not tailored to your situation.